Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 21, 2021; 27(31): 5247-5258
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5247
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5247
Table 3 Eradication success rate in tailored therapy group according to dual priming oligonucleotide polymerase chain reaction results
| Eradication rate | No mutation | A2142G positive | A2143G positive |
| Number of patients who initially enrolled | 81 | 4 | 25 |
| Number of patients with eradication failure | 9 | 0 | 1 |
| Number of patients lost to follow up | 7 | 1 | 1 |
| Number of patients with poor compliance | 0 | 0 | 0 |
| Eradication success rate | |||
| Intention-to-treat | 65/81 (80.25%) | 3/4 (75.00%) | 23/25 (92.00%) |
| Per-protocol | 65/74 (87.84%) | 3/3 (100%) | 23/24 (95.83%) |
- Citation: Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258
- URL: https://www.wjgnet.com/1007-9327/full/v27/i31/5247.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i31.5247